Document is current
Any future updates will be listed below
-
Authors
Byazrova, Maria
Litovkina, Alla
Eckl-Dorna, Julia
Huang, Huey-Jy
Trifonova, Daria
Zghaebi, Mohammed
Smolnikov, Evgenii
Flicker, Sabine
Romanova, Alfira
Stanek, Victoria
Tu, Aldine
Jiang, Tianchi
Campana, Raffaela
Tulaeva, Inna
Vrtala, Susanne
Garib, Victoria
Elisyutina, Olga
Filatov, Alexander
Khaitov, Musa
Skvortsova, Veronika
Valenta, Rudolf
- License Information
-
More Information
Article History
Received: 15 September 2025
Revised: 13 October 2025
Accepted: 16 October 2025
First Online: 13 January 2026
Change Date: 1 February 2026
Change Type: Update
Change Details: The original online version of this article was revised: The Data availability section is corrected.
Declarations
:
: The study was approved by the Ethical Committee of the NRC Institute of immunology FMBA of Russia (Protocol code: #3, 16 February 2018). Each person was informed about the objectives and rules of the study and provided informed consent.
: Not applicable.
: The author Rudolf Valenta has received research grants from Viravaxx AG, Vienna, Austria, HVD Biotech, Vienna, Austria and Worg Pharmaceuticals, Hangzhou, China. He serves as a consultant for HVD and Worg. The author Julia Eckl-Dorna received grants from GSK, Astrazeneca and Sanofi. The other authors have no conflicts of interest to declare. The authors with Russian affiliation declare that they have prepared the article in their “personal capacity” and/or that they are employed at an academic/research institution where research or education is the primary function of the entity.
